PepGen Inc. has announced the pricing of its initial public offering at $3.20 per share, aiming to raise $100 million through the sale of 31.25 million shares. The IPO is being managed by Leerink Partners and Stifel, with the transaction expected to close on September 26, 2025. The funds raised will support clinical trials, including the FREEDOM-DM1 study, and general corporate purposes.